We are live on ! Find out more
TRV

Third Rock Ventures Portfolio holdings

AUM $1.07B
1-Year Est. Return 170.23%
This Fund
S&P 500
This Quarter Est. Return
-15.05%
1 Year Est. Return
+170.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$110M
Cap. Flow
+$440M
Cap. Flow %
41.11%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$696M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$144M
2
LRMR icon
Larimar Therapeutics
LRMR
+$112M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
$622M 58.1%
+14,760,900
New +$696M
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$273M 25.46%
6,442,916
-2,330,157
-27% -$144M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$158M 14.73%
7,393,059
– –
CARM
4
DELISTED
Carisma Therapeutics
CARM
$11.7M 1.09%
242,080
– –
LRMR icon
5
Larimar Therapeutics
LRMR
$384M
$6.72M 0.63%
17,531
-249,306
-93% -$112M

Similar funds

AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
MCC
Mid Continent Capital Chicago, Illinois $1.54B AUM 0.7% 1-Year Est. Return
OA
OFI Advisors Philadelphia, Pennsylvania $1.55B AUM 1.44% 1-Year Est. Return

Third Rock Ventures's Q3 2015 Portfolio in Review

As of Q3 2015, Third Rock Ventures held 5 positions worth $1.07B, up 11% from $961M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Third Rock Ventures deployed $440M of net new capital in Q3 2015, opening 1 new position. Its largest new stake was Global Blood Therapeutics, Inc.: 14,760,900 shares worth $622M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Sage Therapeutics, an estimated $144M trimmed.

  • Third Rock Ventures's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 14,760,900 shares worth $622M.
  • Third Rock Ventures's biggest Q3 2015 reduction was Sage Therapeutics, cutting an estimated $144M.
  • Third Rock Ventures's ten largest holdings make up 100% of its $1.07B portfolio in Q3 2015.
  • Third Rock Ventures opened 1 new position and closed 0 in Q3 2015.
  • Third Rock Ventures's portfolio value rose 11% quarter-over-quarter to $1.07B.

Based on Third Rock Ventures's 13F filing for Q3 2015, filed 3 Nov 2015.